Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Next Previous
X
Search
Trial Profile

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Abbott Laboratories; AbbVie

    • Most Recent Events

    • 13 Jul 2022 Results published in the Clinical Drug Investigation
    • 11 Jul 2022 Status changed from active, no longer recruiting to completed.
    • 03 Jun 2021 Results (at data cut-off: 4 June 2019) assessing long-term efficacy and safety analyses from this study with a median follow-up of approximately 5 years, 3 years, published in the Blood.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top